|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��Ƥ�����ɽ�֢,�ж��� |
|
ϸ������ |
|
�������� |
| ��������������� | |
|
��ʢ |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
�ж��Ա�Ƥ�����ɽ�֢�о���չ
��ʢ, ����
�Ĵ���ѧ����ҽԺƤ���Բ��� �ɶ� 610041
�ж��Ա�Ƥ�����ɽ�֢��һ��������в�����ļ���,����ҩ���շ�,���Ѿ�֤ʵ�����γ�ϸ������������ͻ������֯ѧ����,��FasL-Fas�鵼��ϸ�����߷�Ӧ���ж��Ա�Ƥ�����ɽ�֢��������Ҫ�����á�����ע���ñ����Ըò������Ե�����Ч����
[2] Paul C,Wolkenstein P,Adle H,et al.Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis.Br J Dermatol,1996,134(4):710-714.
[3] Friedmann PS,Strickland I,Pirmohamed M,et al.Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine.Arch Dermatol,1994,130(5):598-604.
[4] Stone N,Sheerin S,Burge S.Toxic epidermal necrolysis and graft vs.host disease:a clinical spectrum but a diagnostic dilemma.Clin Exp Dermatol,1999,24(4):260-262.
[5] Magina S,Lisboa C,Goncalves E,et al.A case of toxic epidermal necrolysis treated with intravenous immunoglobin.Br J Dermatol,2000,142(1):191-192.
[6] Paquet P,Jacob E,Damas P,et al.Treatment of drug-induced toxic epidermal necrolysis(Lyell's syndrome) with intravenous human immunoglobulins.Burns,2001,27(6):652-655.
[7] Correia O,Delgado L,Roujeau JC,et al.Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis:a comparative analysis of serum and blister fluid samples.Arch Dermatol,2002,138(1):29-32.
[8] Correia O,Delgado L,Barbosa IL,et al.CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease:further similarities with toxic epidermal necrolysis.Dermatology,2001,203(3):212-216.
[9] Krammer PH.CD95's deadly mission in the immune system.Nature,2000,407(6805):789-795.
[10] Wolkenstein P,Latarjet J,Roujeau JC,et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.Lancet,1998,352(9140):1586-1589.
[11] Lee SH,Jang JJ,Lee JY,et al.Fas ligand is expressed in normal skin and in some cutaneous malignancies.Br J Dermatol,1998,139(2):186-191.
[12] Viard I,Wehrli P,Bullani R,et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.Science,1998,282(5388):490-493.
[13] French LE,Tschopp J.Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease:potential for therapeutic inhibition.Schweiz Med Wochenschr,2000,130(44):1656-1661.
[14] Nassif A,Bensussan A,Dorothee G,et al.Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.J Invest Dermatol,2002,118(4):728-733.
[15] Stella M,Cassano P,Bollero D,et al.Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins:our experience.Dermatology,2001,203(1):45-49.
[16] Hess DA,Rieder MJ.The role of reactive drug metabolites in immune-mediated adverse drug reactions.Ann Pharmacother,1997,31(11):1378-1387.
[17] Kalgutkar AS,Dalvie DK,O'Donnell JP,et al.On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.Curr Drug Metab,2002,3(4):379-424.